Summary.-Serum lysozyme activity was measured in groups of untreated patients with malignant melanoma, hypernephroma and breast carcinoma. Significant elevation of serum levels of the enzyme was confined to patients with localized disease. In the presence of metastatic disease such elevation was not detected. The rise in serum lysozyme activity was not due to renal damage or any infective process and in the case of malignant melanoma was shown to be associated with infiltration of the tumour mass by macrophages. In vitro studies demonstrated that the macrophages resident in a tumour mass are responsible for releasing lysozyme in large amounts. It is proposed that the elevation of serum lysozyme in these cases may be an indicator of macrophage-mediated host resistance and that the measurement of macrophage products such as lysozyme in the extracellular fluid may under well defined conditions provide useful clinical information concerning host reactions.
IN THE serum of rats bearing syngeneic immunogenic tumours there are elevated levels of lysozyme (mucopeptide n-acetyl muramyl hydrolase EC 3.2.1.17), much of which is released from macrophages resident in the tumour mass and the regional draining lymph nodes (Currie and Eccles, 1976) . In such animals the serum lysozyme levels appear to reflect the degree of macrophage-mediated host resistance and correlate with several features of the natural history of the tumours. This brief report describes an extension of these studies designed to examine serum lysozyme levels in cancer patients to determine whether an assay for lysozyme in the serum can give clinically relevant information about host responses and the biological behaviour of the tumours.
MATERIALS AND METHODS
Lysozyme assay. The lysoplate assay described by Osserman and Lawlor (1966) was adapted for use as previously described (Currie and Eccles, 1976) . A standardized batch of normal human serum was used to calibrate each lysoplate assay.
Patients 8tudied.-Serum samples were obtained from patients with a histologically proven diagnosis of malignant melanoma, hypernephroma or breast carcinoma. The sera were obtained before any treatment was given. Patients were excluded from the study if there was any known unrelated gross pathology or if they were taking any form of medication. None of the patients showed any clinical or laboratory evidence of renal malfunction and none had any known infective process. The individual groups of patients studied and the staging methods employed will be described below. Sera from 21 normal unmatched individuals were also examined. Their ages ranged from 17 to 60 years.
RESULTS

Malignant melanoma
Serum samples from 72 patients with a histologically proven diagnosis of malignant melanoma were assayed for lysozyme 
Hypernephroma
In these 25 patients, marked elevation of the serum lysozyme was found almost exclusively in those cases with disease confined to the kidney (see Fig. 2 ). However, in one patient with a single 1 cm lung metastasis (examined 3 months after nephrectomy) there was significant elevation. Two patients with localized primary tumours had abnormally low levels of lysozyme but both these cases had received preoperative irradiation to the renal area. The difference between ,ere typical cases of fibroadenosis. In the cells were resuspended in serum-free ie carcinoma patients all those with lysoyme-levels above 12-5 ,ug/ml had no evidmedium at 4 X 106/ml. Twenty-ul samnce of metastatic disease. ples of these suspensions were then added to the wells of lysozyme assay group of the T+, No, Mo cases with plates (containing medium 199 as the Jted lysozyme levels. However, as buffer diluent) and were incubated for liagram indicates, a serum lysozyme 24 h at 37TC in a 5% CO2 atmosphere.
bove ,tg/ml in a patient with Standard curves of normal human lysostologically proven primary breast zyme were obtained on the same plates noma is associated with the absence and the results were expressed as ,ug rert metastatic disease. The benign lysozyme/106 cells/24 h. ;t lesions seem to fall into two Cells from these suspensions were also ps. Three cases with inflammatory cultured in RPMI1640 plus 10% foetal ses (2 degenerating cysts and 1 case bovine serum in plastic culture flasks. it necrosis) had abnormally high After two days' incubation the cultures yme levels, whereas the remainder, were washed and trypsinized for 5 min fibroadenosis, were within the normal with 0.1% trypsin. The detached cells
In untreated patients with distant were then assayed for lysozyme release stases the lysozyme levels were not as above. Passaged tumour cells obRcantly different from the normals tained in this way failed to release Gauci and Alexander (1975) who examined the same cell suspensions for macrophage content using a specific anti-human macrophage serum and obtained similar results.
DISCUSSION
If the levels of lysozyme in the serum of cancer patients are a reflection of host resistance, as seems to be the case in an animal model (Currie and Eccles, 1976) certain predictions can be made.
Patients with localized primary tumours should have higher levels than both normal individuals and those with metastatic disease. The data obtained from patients with malignant melanoma, hypernephroma and breast carcinoma are in accord with such a prediction.
The breast carcinoma cases were staged surgically, histologically and by intensive investigation, and it can be seen that those women with a histologically proven primary breast carcinoma who presented with significant elevation in serum lysozyme (above 12*5 /tg/ml) had no detectable metastatic disease. Any further conclusions about the prognostic significance of such an observation must obviously await a prospective controlled study. However, it is tantalizing to note that exactly half the patients with a localized primary breast carcinoma (NoMo) show a significant elevation in serum lysozyme. Fogelson and Lobstein (1954) Cooper et al. (1974) have examined serum lysozyme activity in patients with colo-rectal cancer before and after surgical treatment and indicated that patients with primary tumours had significantly higher serum lysozyme levels than normal controls and that surgical excision led to a significant fall in serum activity. There was also a suggestion that patients with metastatic disease had higher levels than those with localized tumours and long term follow-up studies showed that raised lysozyme levels may occur as a transient phenomenon in recurrent or metastatic disease. They speculated that the elevation of serum lysozyme activity in these patients may reflect a host reaction to the tumour. Subsequently Jedrzejczak and Siekierzynski (1975) criticized this series and stated that raised serum lysozyme levels in cancer patients may be due to increased granulocyte turnover associated with infection and are therefore of no diagnostic or prognostic value. In the animal studies of Currie and Eccles (1976) there was no evidence of any infectious process, and in the patients with malignant melanoma and breast carcinoma, those with the highest lysozyme levels were the patients with primary lesions, none of which were infected. Primary lesions in malignant melanoma are frequently infiltrated with macrophages (Currie, Lejeune and Fairley, 1971 ) and the production of increased amounts of lysozyme is, I suggest, most likely to be due to macrophages resident in the tumour mass or in the regional lymph nodes. Furthermore, single cell suspensions obtained from human malignant melanoma release lysozyme in vitro in a manner similar to that found in the rat tumours where it is associated with the presence of macrophages.
There is an apparent contradiction between the results obtained in the animal model systems (Currie and Eccles, 1976) and those seen in the cancer patients. In general, elevated lysozyme levels in the cancer patients were associated with early or localized disease whereas in the HSBPA rat sarcoma, for instance, the levels in the serum rose progressively with tumour growth. However, the HSBPA tumour is highly immunogenic, does not metastasize at any stage and seems to maintain its high content of macrophages throughout tumour growth. The lysozyme data from the cancer patients suggest that there may be a fall in the macrophage content of tumours as they grow and disseminate. Our studies suggest that localized tumours (malignant melanoma) have a higher macrophage content than do distant metastases. The rat sarcomata studied in our previous paper (Currie and Eccles, 1976) present distinctly different types of biological behaviour. The HSBPA sarcoma already mentioned rarely metastasizes and is associated with high serum lysozyme levels, whereas the highly metastatic tumour (MC3) evokes only low serum levels. These rat sarcomata may be analogues of the various stages in the natural history of human " solid " tumours. A localized primary tumour is under some form of host restraint associated with large numbers of macrophages resident within the tumour mass and its draining regional lymph nodes. This macrophage response could -account for the elevated serum lysozyme levels. The development of metastatic disease due to (or accompanied by) the failure of host resistance is associated with sparse macrophage infiltration of the tumour mass and therefore with lower levels of lysozyme in the serum.
The serum level of lysozyme is affected by many variables such as granulocyte kinetics, renal function and the total number of macrophages and monocytes in the body. Because of this it is unlikely to be of value as a screening test for detecting or even following the progress of cancer patients (Cooper et al., 1974) . However, in the presence of a histo-logically proven primary tumour it may be of value in staging, by identifying those patients in whom some form of host resistance associated with macrophage infiltration is still operating.
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